Literature DB >> 22846611

Intraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis.

Emil M DeGoma1, Benjamin French, Richard L Dunbar, Matthew A Allison, Emile R Mohler, Matthew J Budoff.   

Abstract

BACKGROUND: The intraindividual variability of C-reactive protein (CRP) remains uncertain. Although guidelines suggest stability of serial CRP values comparable to that of cholesterol measures, several studies indicate greater fluctuations of CRP. We sought to compare the intraindividual variability of CRP with that of cholesterol measures using the multi-ethnic study of atherosclerosis (MESA).
METHODS: CRP measurements were available in 760 MESA participants after exclusion of those with comorbidities or medications known to affect CRP or CRP≥10 mg/L. Serial values were available for 255 participants. The intraclass correlation coefficient (ICC) was quantified for CRP, total cholesterol (TC), and non-HDL-cholesterol (non-HDL-C) as the ratio of between-subject variance to the sum of between-subject and within-subject variance. Fluctuation between baseline and follow-up categories was calculated by cross-classifying participants according to baseline tertiles.
RESULTS: The multivariable-adjusted ICC of CRP was 0.62 (95% CI, 0.55-0.68), significantly lower than that of TC (0.75; 95% CI, 0.70-0.81; p = 0.001 vs CRP) and non-HDL-C (0.76; 95% CI, 0.71-0.81; p = 0.001 vs CRP). 51% of participants in the highest baseline CRP tertile had discordant values on follow-up, while 54% and 27% were discordant in the middle and lowest baseline CRP tertiles. Among participants with baseline CRP levels exceeding 3 mg/L, a clinical threshold for higher risk, 69% had subsequent measurements falling within a lower risk category.
CONCLUSIONS: In the MESA cohort, intraindividual variation of CRP was significantly greater than that for cholesterol measures. Our results suggest that further evaluation of CRP variability is needed in large prospective studies using shorter intervals between measurements.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22846611      PMCID: PMC4085141          DOI: 10.1016/j.atherosclerosis.2012.07.017

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  27 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-11-11       Impact factor: 29.690

3.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

4.  Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987.

Authors:  Wolfgang Koenig; Malte Sund; Margit Fröhlich; Hannelore Löwel; Winston L Hutchinson; Mark B Pepys
Journal:  Am J Epidemiol       Date:  2003-08-15       Impact factor: 4.897

Review 5.  34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap?

Authors:  Richard C Pasternak; Jonathan Abrams; Philip Greenland; Lynn A Smaha; Peter W F Wilson; Nancy Houston-Miller
Journal:  J Am Coll Cardiol       Date:  2003-06-04       Impact factor: 24.094

6.  Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993-1998.

Authors:  K Kayaba; S Ishikawa; T Gotoh; N Nago; E Kajii; Y Nakamura; K Kario
Journal:  Jpn Circ J       Date:  2000-04

7.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications.

Authors:  E M Macy; T E Hayes; R P Tracy
Journal:  Clin Chem       Date:  1997-01       Impact factor: 8.327

Review 8.  Biologic variability of C-reactive protein: is the available information reliable?

Authors:  Federica Braga; Mauro Panteghini
Journal:  Clin Chim Acta       Date:  2012-04-14       Impact factor: 3.786

9.  Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA).

Authors:  Holly Kramer; Cong Han; Wendy Post; David Goff; Ana Diez-Roux; Richard Cooper; Sujata Jinagouda; Steven Shea
Journal:  Am J Hypertens       Date:  2004-10       Impact factor: 2.689

10.  Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells.

Authors:  Paolo Calabró; James T Willerson; Edward T H Yeh
Journal:  Circulation       Date:  2003-10-06       Impact factor: 29.690

View more
  26 in total

1.  Trajectories of peripheral interleukin-6, structure of the hippocampus, and cognitive impairment over 14 years in older adults.

Authors:  Andrea L Metti; Howard Aizenstein; Kristine Yaffe; Robert M Boudreau; Anne Newman; Lenore Launer; Peter J Gianaros; Oscar L Lopez; Judith Saxton; Diane G Ives; Stephen Kritchevsky; Abbe N Vallejo; Caterina Rosano
Journal:  Neurobiol Aging       Date:  2015-07-28       Impact factor: 4.673

2.  The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study.

Authors:  Keenan A Walker; B Gwen Windham; Charles H Brown; David S Knopman; Clifford R Jack; Thomas H Mosley; Elizabeth Selvin; Dean F Wong; Timothy M Hughes; Yun Zhou; Alden L Gross; Rebecca F Gottesman
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Reproducibility of novel immune-inflammatory biomarkers over 4 months: an analysis with repeated measures design.

Authors:  Matthew Schenk; Fabian Eichelmann; Matthias B Schulze; Natalia Rudovich; Andreas F Pfeiffer; Romina di Giuseppe; Heiner Boeing; Krasimira Aleksandrova
Journal:  Biomark Med       Date:  2019-06-03       Impact factor: 2.851

4.  Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality.

Authors:  Christina M Parrinello; Pamela L Lutsey; Christie M Ballantyne; Aaron R Folsom; James S Pankow; Elizabeth Selvin
Journal:  Am Heart J       Date:  2015-04-18       Impact factor: 4.749

5.  The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Mahmoud Al Rifai; Michael G Silverman; Khurram Nasir; Matthew J Budoff; Ron Blankstein; Moyses Szklo; Ronit Katz; Roger S Blumenthal; Michael J Blaha
Journal:  Atherosclerosis       Date:  2015-02-07       Impact factor: 5.162

6.  Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Tracey G Simon; Maria Esther Perez Trejo; Robyn McClelland; Ryan Bradley; Michael J Blaha; Irfan Zeb; Kathleen E Corey; Matthew J Budoff; Raymond T Chung
Journal:  Int J Cardiol       Date:  2018-05-15       Impact factor: 4.164

7.  Variability in C-reactive protein is associated with cognitive impairment in women living with and without HIV: a longitudinal study.

Authors:  Leah H Rubin; Lorie Benning; Sheila M Keating; Philip J Norris; Jane Burke-Miller; Antonia Savarese; Krithika N Kumanan; Saria Awadalla; Gayle Springer; Kathyrn Anastos; Mary Young; Joel Milam; Victor G Valcour; Kathleen M Weber; Pauline M Maki
Journal:  J Neurovirol       Date:  2017-10-23       Impact factor: 2.643

8.  Trajectories of inflammatory markers and cognitive decline over 10 years.

Authors:  Andrea L Metti; Kristine Yaffe; Robert M Boudreau; Eleanor M Simonsick; Ryan M Carnahan; Suzanne Satterfield; Tamara B Harris; Hilsa N Ayonayon; Caterina Rosano; Jane A Cauley
Journal:  Neurobiol Aging       Date:  2014-06-06       Impact factor: 4.673

9.  Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Emil M Degoma; Mat D Davis; Richard L Dunbar; Emile R Mohler; Philip Greenland; Benjamin French
Journal:  Atherosclerosis       Date:  2013-03-26       Impact factor: 5.162

Review 10.  A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and immunological health conditions in humans.

Authors:  Ellen T Chang; Hans-Olov Adami; Paolo Boffetta; H James Wedner; Jack S Mandel
Journal:  Crit Rev Toxicol       Date:  2016-01-13       Impact factor: 5.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.